Why You Might Think Of Investing In This FTSE Underdog: AstraZeneca plc

AstraZeneca plc (LON: AZN) could be a contrarian investment opportunity.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Contrarian investors look for stocks that are out of favour with the market. When sentiment is negative then the true value of a stock can be overlooked. I’m trawling the underdogs of the FTSE to identify which of them may not deserve their sub-market PE ratings.

Unloved

AstraZeneca (LSE: AZN) (NYSE: AZN.US) is certainly unloved. At 9.1, its historic P/E is half that of rival GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US). Digital Look shows just 5 out of 35 brokers give it a ‘buy’ rating. And a yield rising year-on-year is a clear sign of a stock supported by its dividend.

Astra’s problem is its well-know patent cliff. Sales dropped by 20% in 2012 as drugs came off-patent, and analysts’ expectations are for continued declines over the next few years. CEO Pascal Soriot has committed Astra to remaining a pure pharma company, and sees its salvation in development of new drugs.  But even he set a modest target of restoring sales in 2018 to their 2011 level.

Safer

I much prefer GSK’s safer, more diversified, strategy. As well as prescription drugs it makes over-the-counter medicines and vaccines. They don’t involve such massive and risky R&D investment.

Indications are that GSK has also overcome its patent cliff, with analysts forecasting an upturn in its drugs revenues. That suggests Astra’s pipeline issues shouldn’t be insurmountable.

Biotech

I have a small holding in Astra. Essentially I see it as a biotech play, but one that pays a fat dividend while it’s developing new drugs.

Astra has targeted three therapeutic areas. This month alone has seen announcements about two biotech company acquisitions and two drugs going to Stage III trials, one for cancer and one for asthma. Global demographics — more, older, wealthier people — underpin demand for whatever the boffins can invent.

Meanwhile Astra’s strong balance sheet, with net gearing of 11% against GSK’s 243%, means the dividend should be safe. Management have relaxed the policy to target two times cover ‘over the investment cycle’ to give them wriggle-room.

Buying opportunity?

Ace investor Neil Woodford is a big fan, with 9% of his Invesco Perpetual funds in each of Astra and GSK. However, either the change of management when he leaves, or investors withdrawing funds from Invesco Perpetual, could see a flow of investment away from Astra.

That’s something I’ll watch. If the shares do weaken in the near term I might add to my holding.  The buy case for Astra needs patience.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

 > Tony owns shares in AstraZeneca and GSK but no other shares mentioned in this article. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »